The amended deal allows Ethicon Endo-Surgery to promote and sell Neoprobe's neo2000 gamma detection systems for cancer diagnosis through the end of 2013.
Neoprobe's gamma detection systems are used in lymphatic mapping for determining various stages of cancer. A radioactive tracing agent is injected directly into the tumor site, and the agent follows the same flow along the lymphatic system that a tumor would follow if it metastasized or spread.
The operative surgeon can then track this flow with a special probe identifying key lymph nodes along the path to be tested for the presence of cancer, according to Neoprobe.
Neoprobe, Cardinal Health ink distribution deal, November 28, 2007
Neoprobe cuts loss on higher sales, October 31, 2007
Cardinal hires Philips executive, August 13, 2007
Neoprobe posts Q2 loss on higher sales, July 26, 2007
Neoprobe signs Cardinal for Lymphoseek sales, July 13, 2007
Copyright © 2007 AuntMinnie.com